Navigation Links
Promising new finding for therapies to treat persistent seizures in epileptic patients
Date:1/16/2013

LOS ANGELES (Jan. 16, 2013) In a promising finding for epileptic patients suffering from persistent seizures known as status epilepticus, researchers reported today that new medication could help halt these devastating seizures. To do so, it would have to work directly to antagonize NMDA receptors, the predominant molecular device for controlling synaptic activity and memory function in the brain.

"Despite the development of new medications to prevent seizures, status epilepticus remains a life-threatening condition that can cause extensive brain damage in the patients that survive these persistent seizures," said David E. Naylor, MD, PhD, a lead researcher at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and corresponding author of the new study. "Our research holds promise for the development of new therapies to treat this devastating condition because we have found a potential new target for medical intervention that should bolster the current standard therapies to treat the acute seizures. It may also prevent the long-term adverse effects of persistent seizure activity on the brain."

The research, reported online in the Neurology of Disease journal, used animal models to assess cellular activity in the brain during persistent seizures. It found that the seizure activity seemed to force the NMDA receptors from the interior to the surface of nerve cells causing their activity to increase by approximately 38%.

"The increased presence of the NMDA receptors on the cell surface during these seizures may explain the successful use of NMDA antagonists medication that inhibits the activity of the NMDA receptors in the brain in the latter stages of a seizure, long after other medications have stopped working," said Dr. Naylor. "We concluded that medications that suppress the activity of the NMDA receptors, in conjunction with other medications, may be successful in stopping persisten
'/>"/>

Contact: Laura Mecoy
lmecoy@labiomed.org
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Promising compound restores memory loss and reverses symptoms of Alzheimers
2. Stanford geoscientist cites critical need for basic research to unleash promising energy sources
3. Alzheimers disease in mice alleviated promising therapeutic approach for humans
4. Stem cells + nanofibers = Promising nerve research
5. Berkeley Lab scientists help develop promising therapy for Huntingtons disease
6. Promising new drug target for inflammatory lung diseases
7. Space research institute awards funding to promising medical products
8. American Health Assistance Foundation announces grants to advance promising vision research
9. 22 of Americas most promising scientists selected as Pew Biomedical Scholars
10. UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure
11. Ultrasensitive biosensor promising for medical diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Promising new finding for therapies to  treat persistent seizures in epileptic patients
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... BOULDER, Colo., September 11, 2012 BiOptix announced continued support ... in BioWest 2012, a leading life sciences showcase ... City Center. "BiOptix continues to believe in the ... Association, noted Rick Whitcomb, President and CEO of ...
... screening technique developed by researchers at the RIKEN Plant ... novel immune-priming compounds in Arabidopsis plants. Discovery ... plant growth or crop yield, establishes the new technique ... crops from damaging pathogens. Plant activators, compounds that ...
... Mich.A strip of glass covered in hairy nanoparticles can ... system, and other toxic metals in fluids. ... Northwestern University and the University of Michigan found that ... common form of mercury pollution, at unprecedentedly small concentrations. ...
Cached Biology News:BiOptix Participates in Leading Life Sciences Event BioWest 2012 2Screening technique uncovers 5 new plant activator compounds 2Measuring mercury levels: Nano-velcro detects water-borne toxic metals 2Measuring mercury levels: Nano-velcro detects water-borne toxic metals 3
(Date:12/19/2014)... 18, 2014 iLab Solutions, the global ... of Siri Bryant as the new Director of Institutional ... Core Implementations. These two new leadership positions were created ... by ensuring that iLab continues to meet the needs ... four years, iLab has been deployed at over 450 ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
(Date:12/17/2014)... December 16, 2014 The Activated ... 2013, which is why IBISWorld updated its original industry ... to benefit from an intensified focus on environmental policy. ... new emission standards for power plants and a range ... to IBISWorld Industry Analyst Sarah Kahn, “a range of ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... are being held to solicit public sentiment on Assembly ... 45 . The bills were introduced to the state legislature ... and parthenogenesis (the process of manipulating the genetic material of ... material from any other cell, in a way that causes ...
... just go bad. Not so often, components that supply power ... case beginning at 11:57 p.m. Monday night with TDS Internet ... and downed dial-up and DSL users en masse, TDS Telecom ... restored at 2:40 a.m. to all users. , ,TDS Internet ...
... determined to give heavy email users something they lack: time and ... a heavy email user, talks about the inspiration for his company, ... world. , , WTN: How much email do you get everyday? ... messages a day from various email accounts with about 70% of ...
Cached Biology Technology:Public Hearing Held for controversial anti-cloning bills 2Public Hearing Held for controversial anti-cloning bills 3Public Hearing Held for controversial anti-cloning bills 4TDS Suffers 29-State System Outage 2TDS Suffers 29-State System Outage 3WTN Interview: Alex Bratton: EmailRX's founder on viruses and spam 2WTN Interview: Alex Bratton: EmailRX's founder on viruses and spam 3
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
PFM8 Antibody...
Biology Products: